Human C1-esterase inhibitor

Generic Name: Human C1-esterase inhibitor

Brand Names: Berinert, Cinryze, Haegarda

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: 6KIC4BB60G

Background: C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.

This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction of the immune system. The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.

Indication: Intravenous and subcutaneous formulations of the human C1-esterase inhibitor are indicated for routine prophylaxis against acute attacks of hereditary angioedema in patients six years of age and older. It is also used to treat these in adult and adolescent patients with hereditary angioedema.

Associated Conditions: Acute attacks of hereditary angioedema, Acute attack of hereditary angioedema of the Abdomen, Acute attack of hereditary angioedema of the Larynx, Acute attack of hereditary angioedema of the face

Associated Therapies: -

Clinical Trials

Genetically engineered pig heart transplantation in non-human primates and humans shows promise for end-stage heart failure

Clinical cardiac xenotransplantation using genetically engineered pig hearts shows promise for end-stage heart failure patients. Recent transplants of 10-GE pig hearts into humans and non-human primates demonstrated survival up to 225 days, indicating potential to alleviate donor organ shortages. Gene edits aimed at preventing rejection and controlling inflammation were key to prolonged xenograft survival.

pharmaphorum.com

4 days ago

Phase 3 trial win sets up rare disease drug filing for CSL

CSL's garadacimab, a once-monthly therapy for hereditary angioedema (HAE), shows efficacy comparable to Takeda's Takhzyro, with 86.5% reduction in monthly attacks. Garadacimab's less frequent dosing could challenge Takhzyro's market dominance, alongside BioCryst's Orladeyo. CSL also markets Berinert and Haegarda for HAE, facing growth challenges from new therapies.

angioedemanews.com

12 days ago

New Treatments for Hereditary Angioedema

Hereditary angioedema (HAE) treatment options have expanded with eight FDA-approved medications and more in development. HAE, a rare genetic disorder, involves C1 esterase inhibitor gene mutations causing severe swelling. While no cure exists, therapies like kallikrein inhibitors (Lanadelumab-flyo, Berotralstat, Ecallantide) and C1 esterase inhibitors (Cinryze, Haegarda, Ruconest, Berinert) aim to prevent and manage attacks.

medicalresearch.com

4 months ago

HAE: The Latest in Clinical Research

Clinical research advancements in Hereditary Angioedema (HAE) are improving treatment options, emphasizing early diagnosis, patient education, personalized medicine, and overcoming development challenges. Staying updated through medical journals, conferences, and professional networks is crucial for healthcare professionals.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy